| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9319360 | European Urology | 2005 | 8 Pages |
Abstract
Combined HDR brachytherapy with Iridium 192 is an alternative treatment option for patients with localized prostate cancer. Initial PSA value, risk group, and age are important prognostic factors for progression free survival.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Serdar Deger, Dirk Boehmer, Jan Roigas, Tania Schink, Klaus Dieter Wernecke, Thomas Wiegel, Wolfgang Hinkelbein, Volker Budach, Stefan A. Loening,